ANDA 85532, held by Watson Labs. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 85532 (Hydralazine Hydrochloride), held by Watson Labs, was first approved by FDA on Apr 14, 1977, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 14, 1977 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydralazine Hydrochloride25MG ยท tablet;oral | Hydralazine Hydrochloride | Discontinued |
| Dec 23, 1988 | Supplement 29Labeling | Approved | None posted |
| Apr 14, 1977 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters